Keep checking for updates and new content.

Active Surveillance

15-year metastasis-free survival in men on active surveillance in The Netherlands

May 7, 2017

According to new data reported at the annual meeting of the European Association of Urology in London, active surveillance of men diagnosed with low-risk prostate cancer was not associated with an elevated risk for metastatic disease at 15 years of follow-up. Read the article here.

Read the article or watch the video →

What influences opting out of active surveillance?

April 9, 2017

A man’s race/ethnicity might influence decision-making regarding opting for active treatment as well as undergoing serial biopsies during active surveillance, according to a recent study. Read the article here.

Read the article or watch the video →

Prostate Cancer: New Directions With Active Surveillance

January 2, 2017

Howard Wolinsky, a journalist based in the Chicago area, was diagnosed with early prostate cancer in 2010. After over 5 years of active surveillance, he describes his continuing quest to make the best — and most informed — decision about his care. Read the article here.

Read the article or watch the video →

Prostate Imaging Reporting and Data System score of four or more: active surveillance no more

January 2, 2017

The introduction of multiparametric MRI (mpMRI) has improved the diagnosis and risk stratification of intermediate and high-risk prostate cancer. In addition to diagnosis, mpMRI has increasingly become a useful tool for monitoring the prostate cancer risk of patients on active surveillance (AS) programmes. Long-term data indicates that there is no oncological benefit for AS programmes […]

Read the article or watch the video →

Preventing Overtreatment of Prostate Cancer: New Model Identifies Ideal Patients for Active Surveillance

October 23, 2016

A new care model for patients with low-risk prostate cancer may help prevent disease overtreatment. This evidence-based approach uses best practices to select patients to avoid disease overtreatment. Results from a 3-year study recently published in Urology indicate that active surveillance (AS) rates nearly doubled after this model was adopted. Read the article here.

Read the article or watch the video →

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

September 21, 2016

This New England Journal of Medicine article gives  the results of a randomized trial of 3 possible prostate cancer treatments.  It is rather long and academic, but shows similar results for the 3 options. Read the article here.

Read the article or watch the video →

Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort.

July 24, 2016

To examine the feasibility of active surveillance for low volume Gleason sum (GS) 3 + 4 disease compared to GS 3 + 3 disease. Retrospective review of 929 patients, with biopsy proven GS 3 + 3 and 3 + 4 PCa, undergoing upfront radical prostatectomy (RP) was performed. Read the article.

Read the article or watch the video →

More than 3 percent of men on active surveillance for prostate cancer may have metastases

July 3, 2016

Investigators at the Sunnybrook Health Sciences Centre, University of Toronto initiated a study to assess the risk factors for metastases in patients on active surveillance. About three percent of patients on surveillance had metastasis by a median of seven years after diagnosis. This risk increased to ten percent in patients with Gleason score (GS) 7. […]

Read the article or watch the video →

ASCO Endorses Localized Prostate Cancer Guideline

May 23, 2016

A panel of experts at the American Society of Clinical Oncology (ASCO) have reviewed and endorsed Cancer Care Ontario’s guideline on Active Surveillance for the Management of Localized Prostate Cancer. The guidelines, published in May 2015, “are clear, thorough, and based upon the most relevant scientific evidence,” wrote Ronald C. Chen, MD, MPH, associate professor […]

Read the article or watch the video →

African American men with prostate cancer have significantly lower PSA density than Caucasian men

February 15, 2016

A new study published in The Journal of Urology® revealed that African American men with Gleason score 3+3=6 prostate cancer (PCa) produce less prostate specific antigen (PSA) and have significantly lower PSA density (PSAD) than Caucasian men. These findings could have important implications when selecting patients for inclusion in active PCa surveillance programs. Read the […]

Read the article or watch the video →